| 3.17 0.07 (2.26%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.06 |
1-year : | 4.74 |
| Resists | First : | 3.48 |
Second : | 4.06 |
| Pivot price | 3.15 |
|||
| Supports | First : | 3.04 |
Second : | 2.76 |
| MAs | MA(5) : | 3.21  |
MA(20) : | 3.09 |
| MA(100) : | 2.95 |
MA(250) : | 3.24 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 52.8 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 5.3 | Low : | 1.84 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACHV ] has closed below upper band by 45.8%. Bollinger Bands are 52.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.19 - 3.2 | 3.2 - 3.21 |
| Low: | 3 - 3.01 | 3.01 - 3.03 |
| Close: | 3.15 - 3.17 | 3.17 - 3.19 |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Thu, 09 Oct 2025
Recent uptick might appease Achieve Life Sciences, Inc. (NASDAQ:ACHV) institutional owners after losing 33% over the past year - simplywall.st
Thu, 09 Oct 2025
Recent uptick might appease Achieve Life Sciences, Inc. (NASDAQ:ACHV) institutional owners after losing 33% over the past year - Sahm
Thu, 02 Oct 2025
161,000-Share Option Grant: Achieve Life Sciences Awards to 5 New Hires — 10‑Year Term, 25% Vests After 1 Year - Stock Titan
Thu, 02 Oct 2025
Achieve Life Sciences Announces Granting of New Hire Inducement Awards - Yahoo Finance
Tue, 30 Sep 2025
Achieve Life Sciences: Promising Pipeline But High Risks Makes Me Hold For Now (NASDAQ:ACHV) - Seeking Alpha
Mon, 22 Sep 2025
6M COPD Smokers Could Benefit: Achieve's New Drug Matches Regular Population Quit Rates in Major Trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 61.4 (%) |
| Shares Short | 4,390 (K) |
| Shares Short P.Month | 5,180 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.83 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.7 % |
| Return on Equity (ttm) | -120.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -2.15 |
| PEG Ratio | 0 |
| Price to Book value | 3.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|